Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myocarditis I: Introduction01:21

Myocarditis I: Introduction

368
Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
368
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

8.7K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
8.7K
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

794
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
794
Structure and Function of Platelets01:18

Structure and Function of Platelets

2.9K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
2.9K
MicroRNAs01:22

MicroRNAs

3.8K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.8K
MicroRNAs01:22

MicroRNAs

23.9K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
23.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of Acute Exercise and 12-Week High-Intensity Interval Training on Inflammatory Biomarkers in Stable Coronary Artery Disease: A Randomized Controlled Trial.

Journal of the American Heart Association·2026
Same author

Apixaban Concentrations and Effects on Coagulation in Patients With Nephrotic Syndrome.

Kidney medicine·2025
Same author

Psychometric properties of patient-related outcome measures used for patients surviving a pulmonary embolism: A systematic review.

Thrombosis research·2025
Same author

European Journal of Heart Failure consensus statement. Heart failure pharmacotherapy for patients with heart failure with reduced ejection fraction and concomitant atrial fibrillation: Review of evidence and call to action.

European journal of heart failure·2025
Same author

Development of a questionnaire investigating the physical and psychological well-being and need for rehabilitative strategies in patients with pulmonary embolism.

Journal of patient-reported outcomes·2025
Same author

Effect of hyperthermic intraperitoneal chemotherapy on thrombin generation and fibrinolysis.

International journal of colorectal disease·2025

Related Experiment Video

Updated: Jan 14, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.6K

MicroRNA dynamics and their link to platelet function following acute ST-segment elevation myocardial infarction.

Oliver Buchhave Pedersen1, Erik Lerkevang Grove2, Steen Dalby Kristensen2

  • 1Thrombosis and Haemostasis Research Unit, Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark; Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark.

Thrombosis Research
|October 23, 2025
PubMed
Summary

MicroRNA (miR) expression changes in ST-segment elevation myocardial infarction (STEMI) patients. Several miRs correlate with platelet function, suggesting they may serve as biomarkers for antiplatelet therapy efficacy.

Keywords:
Acute myocardial infarctionPlatelet activationPlatelet function testsmicroRNAs

More Related Videos

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
04:41

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

8.6K
Dynamic Proteomic and miRNA Analysis of Polysomes from Isolated Mouse Heart After Langendorff Perfusion
07:54

Dynamic Proteomic and miRNA Analysis of Polysomes from Isolated Mouse Heart After Langendorff Perfusion

Published on: August 29, 2018

9.0K

Related Experiment Videos

Last Updated: Jan 14, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.6K
Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
04:41

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

8.6K
Dynamic Proteomic and miRNA Analysis of Polysomes from Isolated Mouse Heart After Langendorff Perfusion
07:54

Dynamic Proteomic and miRNA Analysis of Polysomes from Isolated Mouse Heart After Langendorff Perfusion

Published on: August 29, 2018

9.0K

Area of Science:

  • Cardiovascular Medicine
  • Molecular Biology
  • Biomarker Discovery

Background:

  • Reduced efficacy of antiplatelet therapy is noted in ST-segment elevation myocardial infarction (STEMI) patients.
  • MicroRNAs (miRs) are investigated as potential biomarkers for platelet function and antiplatelet therapy response.

Purpose of the Study:

  • To investigate changes in miR expression from acute STEMI to a stable phase.
  • To evaluate the association of miR expression with platelet function at both time points.
  • To assess miRs as potential biomarkers for antiplatelet therapy efficacy.

Main Methods:

  • Patients with acute STEMI undergoing primary percutaneous coronary intervention were enrolled.
  • Blood samples were collected within 24 hours and at 2-3 months post-admission.
  • Expression of candidate miRs, platelet reactivity markers, and thromboxane B2 were measured.

Main Results:

  • Seven miRs (miR-15a-5p, miR-21-5p, miR-26b-5p, miR-126-3p, miR-150-5p, miR-223-3p, miR-423-5p) showed differential expression between baseline and follow-up.
  • miR-26b-5p correlated with fibrinogen receptor expression on platelets at baseline.
  • miR-93-5p was associated with platelet aggregation at follow-up.

Conclusions:

  • Differential expression of seven miRs was observed between acute STEMI and a stable phase.
  • Several miRs demonstrated links to platelet function, indicating their potential as biomarkers.
  • A single miR may not be sufficient to predict platelet function and antiplatelet therapy effectiveness.